Silvergate Pharmaceuticals receives FDA approval for Qbrelis
New Open Access Journal Publishes its First Issue, "Nanoparticles in Medicine"
Bioengineering & Translational Medicine’s special issue focuses on the targeting, optimization and clinical applications of nanoparticles
FIREFLY MEDICAL RECEIVES INVESTMENT FROM CARLTON-HARVEY GROUP TO EXPAND BUSINESS OPERATIONS
In addition to making a significant equity investment in the company, CHG will also assume management control of Firefly Medical. CHG Principal Trevor
Carlton will serve as chief executive officer, and CHG Principal Stuart Harvey will serve as president. Current Firefly Medical CEO, Patrick Bols,
will join the executive committee and become board chairman.
“This investment will help ensure that Firefly has the resources and expertise it needs to realize the IVEA’s full market potential,” says Bols. “We’re
pleased to partner with CHG, because they have the foresight to identify the opportunity before them and the experience to pursue it effectively.”
PierianDx and ArcherDX Announce Partnership Benefiting NGS Clinical Labs
ST LOUIS/BOULDER (July 12, 2016) – ArcherDX and PierianDx today announced co-marketing and licensing agreements that will provide enhanced NGS testing
capabilities to clinical labs. Under the terms of the agreement, PierianDx will integrate Archer® targeted NGS testing pipelines into the PierianDx
Clinical Genomicist Workspace™ (CGW), the leading cloud-based platform that provides clinical labs more streamlined and accurate NGS data analysis,
interpretation, and reporting.
Highly potent autophagy-inducing peptides now exclusively available from Novus Biologicals, a Bio-Techne brand
MINNEAPOLIS, Minnesota [July 18, 2016] – Bio-Techne Corporation, a global life sciences company providing innovative biotechnology research tools and instruments
for the academic, biotech, pharma and diagnostic communities announced today the launch of several new products for the study of autophagy. The Tat-L11,
Tat-D11, and Tat-L11S Control Peptides are available exclusively under the Novus Biologicals brand. Autophagy is a biological process that allows the orderly degradation and recycling of cellular components and is involved in numerous pathological/physiological processes, including cancer, metabolic and neurodegenerative disorders, and cardiovascular/pulmonary diseases.
MPLN partners with ArcherDX to offer Archer NGS assays to global biopharma customers
Boulder, COLORADO – ArcherDX, Inc., has announced that Molecular Pathology Laboratory Network, Inc. (MPLN) is now a Certified Service
Provider of Archer® FusionPlex® NGS assays. MPLN will offer a custom sarcoma analysis service that includes the FusionPlex Sarcoma NGS assay as part
of their services to customers in the biotechnology and pharmaceutical industries.
ViroCyt acquired by Sartorius
VIROCYT® ACQUIRED BY SARTORIUS
LABS, Inc. Rebrands
- CU Boulder Study: Federally-Funded Laboratories and Institutions Have a $2.6 Billion Annual Impact in Colorado
- New Study Shows Biodesix’s VeriStrat Changes Treatment Decisions for Lung Cancer Patients; Reduces Over-Treatment at End of Life
- Flagship Bioscience: Is PD-L1 Harmonization on the Horizon?
- InDevR Launches Next-Generation Software for the Cypher One™ System
- ARCA biopharma Announces Fiscal Year 2016 Financial Results and Provides Business Update